Miraqules co-founder and CEO Sabir Hossain always knew he wanted to follow in his father’s footsteps and run his own business. But he never expected to start a biotech company focused on technology that could help his father, who nearly died from blood loss in a near-tragic accident a few years ago.
Bengaluru-based Miracles has developed a powdered nanotechnology that mimics blood clotting proteins. Blood coagulation powder rapidly forms fibrous compounds at room temperature, has a high volume ratio, and absorbs blood quickly when applied.
“This is a product that gives you instant feedback,” Hossein told TechCrunch. “If someone is bleeding, you apply it and it stops the bleeding. All of this happens within a minute or two.”
Miraqules is a Startup Battlefield Top 20 finalist and will be announcing the technology on stage at TechCrunch Disrupt 2025 in San Francisco this week.
Hossain said he developed the technology almost by accident.
He attended graduate school in biomedical engineering and began working in a lab focused on biomaterials. My job there was basically to emulate the work of PhD students.
“Actually, I was really bad at it,” Hossein said. “Her job was to create 3D structures that would help bone tissue grow and generate bone. Each time she synthesized that material, it would break down.”
tech crunch event
san francisco
|
October 27-29, 2025
One day he took the decomposed particles and ground it into powder. He took the powder to a group studying blood clotting, which had struggled to mix the solution properly, to see if it had any effect. And it worked.
“It probably clotted the whole blood within five to 10 seconds. I rushed to the professor and started thinking about what happened from there,” Hossain said. “We came up with a completely new process of combining off-the-shelf materials into nanomaterials that mimic blood clotting proteins.”
Hossain then teamed up with his childhood friend Mubeen Midda to develop a technology that could be taken out of the lab with as little funding as possible.
Since then, the company has been able to obtain 11 patents in seven countries, including India, the United States, and Israel.
Miraqules’ technology is already being piloted in trauma care centers in India, and the company expects to receive regulatory approval in India in the coming months. It is also scheduled to receive approval from the U.S. Food and Drug Administration in 2026.
“One of the things we did from the beginning was go directly to the U.S. FDA. There’s something called a pre-filing. We tried to get feedback from the FDA about what else we needed to do to get this product approved. That was very helpful to us.”
The company reached these milestones with less than $700,000 in funding, primarily from grants.
Miraqules plans to ramp up its implementation and testing program over the next year. It has already received potential interest from 10 different hospital chains in India and the Israel Defense Forces.
If you want to learn directly from Miraqules, see more pitches, attend valuable workshops, and make connections that drive business results, visit here to learn more about this year’s Disrupt, taking place in San Francisco from October 27th to 29th.
